Zantac Litigation Group
Ranitidine, or Zantac, is a commonly used drug to treat heartburn. Zantac has been available since 1983 and was approved for over the counter use in 1995. Unfortunately, recent studies by the FDA have revealed that Zantac may contain extremely high levels of NDMA, which is known to cause liver, stomach, digestive tract, colorectal, bladder, prostate, and pancreatic cancer. Formed in 2020, the Zantac Litigation assists AAJ members litigating these cases.
The group formed in 2020.
AAJ Winter and Annual conventions
Litigation Group members, visit AAJ's Community Center to connect with your colleagues, search discussion archives, download documents, update your list server settings, and more. Lit Group Member Login